Blog
About

4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Impaired mineral homeostasis affecting calcium, phosphate, and magnesium is a result of parathyroid hormone (PTH) deficiency in hypoparathyroidism. The current standard of treatment with active vitamin D and oral calcium does not control levels of these major minerals. Recombinant full-length human PTH 1-84 (rhPTH[1-84]) is being developed for the treatment of hypoparathyroidism.

          Related collections

          Author and article information

          Journal
          Clin Ther
          Clinical therapeutics
          1879-114X
          0149-2918
          May 2014
          : 36
          : 5
          Affiliations
          [1 ] Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota. Electronic address: clarke.bart@mayo.edu.
          [2 ] PRACS Institute, San Antonio, Texas.
          [3 ] NPS Pharmaceuticals, Inc, Bedminster, New Jersey.
          Article
          S0149-2918(14)00195-7
          10.1016/j.clinthera.2014.04.001
          24802860
          Copyright © 2014 The Authors. Published by EM Inc USA.. All rights reserved.

          Comments

          Comment on this article